Myocardial Infarction
📧 Sign up to get email alerts when something new happens for Myocardial Infarction.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-12-30Clinical Trial Update: Salt Sensitivity, Cardiovascular and Metabolic Disease
A completed clinical trial investigating salt sensitivity in cardiovascular and metabolic diseases.
-
CLINICAL_TRIALS trial_result · 2015-12-29Clinical Trial Update: Montreal Heart Attack Readjustment Trial (M-HART) [Phase 3]
Phase 3 Montreal Heart Attack Readjustment Trial (M-HART) sponsored by McGill University has completed. The trial addresses cardiovascular c…
-
CLINICAL_TRIALS trial_result · 2015-12-24Clinical Trial Update: Heart Rate Variability and Sudden Cardiac Death
The completed trial investigated the relationship between heart rate variability and sudden cardiac death in patients with cardiovascular an…
-
CLINICAL_TRIALS trial_result · 2015-12-17Clinical Trial Update: ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study
The ARgentinean Risk Assessment Registry in Acute Coronary Syndrome (ARRA-RACS) has completed enrollment and posted results.
-
FDA approval · 2015-12-17FDA Approved: VALSARTAN — Supplemental Application (Ohm Laboratories Inc.)
FDA approved a supplemental application for VALSARTAN from Ohm Laboratories Inc. (ANDA077492).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-12-11FDA Approved: VALSARTAN — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for VALSARTAN submitted by Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2015-12-09Clinical Trial Update: Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [Phase 3]
Phase 3 trial update reporting the effects of ticagrelor on preventing cardiovascular events in patients with prior myocardial infarction, c…
-
CLINICAL_TRIALS trial_result · 2015-12-08Clinical Trial Update: Earlobe Creases Predict Prognosis in Chinese Patients With Acute Myocardial Infarction
A clinical trial update examines whether earlobe creases or ear abnormalities can predict prognosis in Chinese patients with acute myocardia…
-
CLINICAL_TRIALS trial_result · 2015-12-08Clinical Trial Update: United Coronary Biobanks
The update notes that the United Coronary Biobanks trial, sponsored by UMC Utrecht, related to coronary artery disease and acute coronary sy…
-
FDA approval · 2015-12-08FDA Approved: EPTIFIBATIDE — Original Application (Eugia US LLC)
FDA approved Eugia US LLC's original ANDA for Eptifibatide, a GP IIb/IIIa inhibitor used to prevent clot formation in patients with acute co…
-
CLINICAL_TRIALS withdrawal · 2015-12-07Clinical Trial Update: Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction [NA]
A clinical trial evaluating acetaminophen to prevent ischemic oxidative reperfusion injury during PCI for acute myocardial infarction was wi…
-
CLINICAL_TRIALS withdrawal · 2015-12-04Clinical Trial Update: TandemHeart to Reduce Infarct Size (TRIS Trial) [NA]
The TRIS Trial evaluating TandemHeart to reduce infarct size in acute myocardial infarction has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-12-03Clinical Trial Update: Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events [Phase 2, Phase 3]
Phase 2/3 trial investigating aspirin resistance and stroke risk through platelet function analysis in patients with ischemic events.
-
CLINICAL_TRIALS trial_result · 2015-12-02Clinical Trial Update: IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting [Phase 2]
Phase 2 trial evaluating autologous CD133+ stem cell therapy in patients undergoing coronary artery bypass grafting has completed.
-
CLINICAL_TRIALS trial_result · 2015-12-02Clinical Trial Update: The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling [Phase 4]
This Phase 4 trial update examines how different doses of valsartan and a genetic polymorphism influence post-myocardial infarction ventricu…
-
FDA approval · 2015-11-25FDA Approved: QUINAPRIL — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for Quinapril by Cipla USA Inc., indicating an approval of an additional Quinapril product or labeli…
-
CLINICAL_TRIALS withdrawal · 2015-11-25Clinical Trial Update: Biomarkers for Postoperative Myocardial Infarction in Cardiac Surgery.
A clinical trial investigating biomarkers for postoperative myocardial infarction after cardiac surgery has been withdrawn.
-
FDA approval · 2015-11-24FDA Approved: QUINAPRIL — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Quinapril hydrochloride from Aurobindo Pharma Limited, enabling the generic product Quinapril hy…
-
FDA approval · 2015-11-20FDA Approved: VALSARTAN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved a supplemental application for valsartan submitted by Lupin Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2015-11-20Clinical Trial Update: Protective Effect of EPA on Cardiovascular Events [Phase 4]
Phase 4 clinical trial update reporting on the potential protective effect of eicosapentaenoic acid (EPA) against cardiovascular events. The…
-
FDA approval · 2015-11-13FDA Approved: HEPARIN SODIUM — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for Heparin Sodium submitted by Fresenius Kabi USA, LLC (NDA 017651). The approval updates labeling …
-
FDA approval · 2015-11-09FDA Approved: VALSARTAN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for valsartan from Aurobindo Pharma Limited, allowing changes to the approved generic product.
-
CLINICAL_TRIALS trial_result · 2015-11-09Clinical Trial Update: Impact of Initial Diagnosis on Mortality for Patients Hospitalised With Acute Myocardial Infarction
A completed clinical trial update evaluating whether the initial diagnosis as STEMI vs NSTEMI influences mortality in patients hospitalized …
-
CLINICAL_TRIALS research · 2015-11-05Clinical Trial Update: NORVIT and WENBIT - Long-term Follow-up
A long-term follow-up update on the NORVIT and WENBIT trials evaluating vitamin supplementation (folic acid with vitamins B6 and B12) in pat…
-
FDA approval · 2015-10-30FDA Approved: VALSARTAN — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for VALSARTAN by Mylan Pharmaceuticals Inc.